ADVERSE REACTIONS Worldwide, over 2900 patients have been treated with rabeprazole in Phase II-III clinical trials involving various dosages and durations of treatment. In general, rabeprazole treatment has been well-tolerated in both short-term and long-term trials. The adverse events rates were generally similar between the 10 and 20 mg doses. ![]() ![]() ![]() Aciphex PI rev-11 ver-1 revised August 2003 | ||||
advertisement




Email this article
Printer friendly
Bookmark this page












